Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model

Author:

Gattinger Pia1ORCID,Kratzer Bernhard2ORCID,Sehgal Al Nasar Ahmed2,Ohradanova-Repic Anna3ORCID,Gebetsberger Laura3,Tajti Gabor3,Focke-Tejkl Margarete14ORCID,Schaar Mirjam1,Fuhrmann Verena1,Petrowitsch Lukas5ORCID,Keller Walter5ORCID,Högler Sandra6ORCID,Stockinger Hannes3ORCID,Pickl Winfried F.2,Valenta Rudolf1478

Affiliation:

1. Division of Immunopathology, Department of Pathophysiology and Allergy Research, Infectiology and Immunology, Center for Pathophysiology, Medical University of Vienna, 1090 Vienna, Austria

2. Institute of Immunology, Infectiology and Immunology, Center for Pathophysiology, Medical University of Vienna, 1090 Vienna, Austria

3. Institute for Hygiene and Applied Immunology, Infectiology and Immunology, Center for Pathophysiology, Medical University of Vienna, 1090 Vienna, Austria

4. Karl Landsteiner University of Health Sciences, 3500 Krems, Austria

5. Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, 8010 Graz, Austria

6. Unit of Laboratory Animal Pathology, Institute of Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria

7. Laboratory for Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, 119991 Moscow, Russia

8. NRC Institute of Immunology FMBA of Russia, 115478 Moscow, Russia

Abstract

Background: COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a recurrent endemic disease affecting the whole world. Since November 2021, Omicron and its subvariants have dominated in the spread of the disease. In order to prevent severe courses of disease, vaccines are needed to boost and maintain antibody levels capable of neutralizing Omicron. Recently, we produced and characterized a SARS-CoV-2 vaccine based on a recombinant fusion protein consisting of hepatitis B virus (HBV)-derived PreS and two SARS-CoV-2 wild-type RBDs. Objectives: To develop a PreS-RBD vaccine which induces high levels of Omicron-specific neutralizing antibodies. Methods: We designed, produced, characterized and compared strain-specific (wild-type: W-PreS-W; Omicron: O-PreS-O), bivalent (mix of W-PreS-W and O-PreS-O) and chimeric (i.e., W-PreS-O) SARS-CoV-2 protein subunit vaccines. Immunogens were characterized in vitro using protein chemical methods, mass spectrometry, and circular dichroism in combination with thermal denaturation and immunological methods. In addition, BALB/c mice were immunized with aluminum–hydroxide-adsorbed proteins and aluminum hydroxide alone (i.e., placebo) to study the specific antibody and cytokine responses, safety and Omicron neutralization. Results: Defined and pure immunogens could be produced in significant quantities as secreted and folded proteins in mammalian cells. The antibodies induced after vaccination with different doses of strain-specific, bivalent and chimeric PreS-RBD fusion proteins reacted with wild-type and Omicron RBD in a dose-dependent manner and resulted in a mixed Th1/Th2 immune response. Interestingly, the RBD-specific IgG levels induced with the different vaccines were comparable, but the W-PreS-O-induced virus neutralization titers against Omicron (median VNT50: 5000) were seven- and twofold higher than the W-PreS-W- and O-PreS-O-specific ones, respectively, and they were six-fold higher than those of the bivalent vaccine. Conclusion: Among the tested immunogens, the chimeric PreS-RBD subunit vaccine, W-PreS-O, induced the highest neutralizing antibody titers against Omicron. Thus, W-PreS-O seems to be a highly promising COVID-19 vaccine candidate for further preclinical and clinical evaluation.

Funder

Austrian Science Fund

the Country of Lower Austria

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3